We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+32.84%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.89B
AUM Growth
+$976M
Cap. Flow
+$388M
Cap. Flow %
7.92%
Top 10 Hldgs %
67.65%
Holding
40
New
10
Increased
13
Reduced
7
Closed
5

Top Buys

1
INSM icon
Insmed
INSM
+$193M
2
BLTE
Belite Bio
BLTE
+$187M
3
MAZE
Maze Therapeutics
MAZE
+$121M
4
CYTK icon
Cytokinetics
CYTK
+$94.1M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$91.4M

Top Sells

1
CDTX
Cidara Therapeutics
CDTX
+$168M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$103M
3
SRRK icon
Scholar Rock
SRRK
+$82.3M
4
ABVX
Abivax
ABVX
+$76.3M
5
URGN icon
UroGen Pharma
URGN
+$55.5M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$663M 13.55%
5,774,016
+50,000
+0.9% +$4.41M
RVMD icon
2
Revolution Medicines
RVMD
$39.6B
$647M 13.23%
6,655,703
+11,300
+0.2% +$1.14M
NUVL icon
3
Nuvalent
NUVL
$545M 11.15%
5,324,433
+55,000
+1% +$5.61M
PCVX icon
4
Vaxcyte
PCVX
$8.12B
$279M 5.69%
4,793,020
+725,000
+18% +$39.4M
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.28B
$232M 4.74%
7,365,038
+823,828
+13% +$23.8M
GMAB icon
6
Genmab
GMAB
$17.6B
$214M 4.37%
7,967,836
+928,002
+13% +$27.8M
INSM icon
7
Insmed
INSM
$23.5B
$205M 4.19%
+1,254,488
New +$193M
TARS icon
8
Tarsus Pharmaceuticals
TARS
$2.61B
$180M 3.67%
2,562,154
– –
BLTE
9
Belite Bio
BLTE
$6.02B
$178M 3.63%
+1,114,784
New +$187M
ERAS icon
10
Erasca
ERAS
$6.65B
$168M 3.44%
10,392,702
-3,766,393
-27% -$44.5M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$142M 2.9%
+3,574,048
New +$91.4M
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1B
$120M 2.44%
8,020,576
+476,404
+6% +$10.6M
TERN
13
DELISTED
Terns Pharmaceuticals
TERN
$117M 2.39%
2,216,499
+1,406,213
+174% +$57.8M
ORKA
14
Oruka Therapeutics
ORKA
$5.59B
$114M 2.33%
2,320,316
+610,000
+36% +$21.2M
APGE icon
15
Apogee Therapeutics
APGE
$10.1B
$113M 2.32%
1,348,243
+225,000
+20% +$16.3M
SYRE icon
16
Spyre Therapeutics
SYRE
$8.7B
$98.7M 2.02%
1,957,266
+490,000
+33% +$18.5M
CYTK icon
17
Cytokinetics
CYTK
$10.9B
$97.6M 1.99%
+1,480,857
New +$94.1M
ABVX
18
Abivax
ABVX
$11.9B
$86M 1.76%
772,473
-645,000
-46% -$76.3M
TNGX icon
19
Tango Therapeutics
TNGX
$4.65B
$83.9M 1.71%
+4,009,679
New +$55.8M
MAZE
20
Maze Therapeutics
MAZE
$1.56B
$81.9M 1.67%
+2,744,399
New +$121M
TYRA icon
21
Tyra Biosciences
TYRA
$1.91B
$78.7M 1.61%
+2,054,991
New +$66.5M
VRDN icon
22
Viridian Therapeutics
VRDN
$1.99B
$61.6M 1.26%
3,148,893
+1,705,791
+118% +$50.7M
SRRK icon
23
Scholar Rock
SRRK
$6.33B
$60.3M 1.23%
1,226,080
-1,836,077
-60% -$82.3M
MIRM icon
24
Mirum Pharmaceuticals
MIRM
$7.25B
$57.7M 1.18%
+625,000
New +$58.8M
EYPT icon
25
EyePoint Inc
EYPT
$1.12B
$40.5M 0.83%
3,142,437
-549,038
-15% -$8.21M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Paradigm Biocapital Advisors held 40 positions worth $4.89B, up 25% from $3.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Paradigm Biocapital Advisors deployed $388M of net new capital in Q1 2026, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Insmed: 1,254,488 shares worth $205M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Scholar Rock, an estimated $82.3M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2026 buy was Insmed: 1,254,488 shares worth $205M.
  • Paradigm Biocapital Advisors added most to Terns Pharmaceuticals in Q1 2026, an estimated $57.8M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2026 reduction was Scholar Rock, cutting an estimated $82.3M.
  • Paradigm Biocapital Advisors fully exited Cidara Therapeutics in Q1 2026, selling an estimated $168M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 68% of its $4.89B portfolio in Q1 2026.
  • Paradigm Biocapital Advisors opened 10 new positions and closed 5 in Q1 2026.
  • Paradigm Biocapital Advisors's portfolio value rose 25% quarter-over-quarter to $4.89B.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.